Characterisation of endogenous A2A and A2B receptor-mediated cyclic AMP responses in HEK 293 cells using the GloSensor™ biosensor: Evidence for an allosteric mechanism of action for the A2B-selective antagonist PSB 603

Joelle Gouldinga,b, Lauren T. Maya,1, Stephen J. Hilla,b,*

a Division of Physiology, Pharmacology and Neuroscience, School of Life Sciences, University of Nottingham, Nottingham NG7 2UH, UK
b Centre of Membrane Proteins and Receptors (COMPARE), University of Birmingham and University of Nottingham, Midlands, UK

Abstract

Endogenous adenosine A2B receptors (A2BAR) mediate cAMP accumulation in HEK 293 cells. Here we have used a biosensor to investigate the mechanism of action of the A2BAR antagonist PSB 603 in HEK 293 cells. The A2A agonist CGS 21680 elicited a small response in these cells (circa 20% of that obtained with NECA), suggesting that they also contain a small population of A2A receptors. The responses to NECA and adenosine were antagonised by PSB 603, but not by the selective A2AAR antagonist SCH 58261. In contrast, CGS 21680 responses were not antagonised by high concentrations of PSB 603, but were sensitive to inhibition by SCH 58261. Analysis of the effect of increasing concentrations of PSB 603 on the response to NECA indicated a non-competitive mode of action yielding a marked reduction in the NECA EMAX with no significant effect on EC50 values. Kinetics analysis of the effect of PSB 603 on the A2BAR-mediated NECA responses confirmed a saturable effect that was consistent with an allosteric mode of antagonism. The possibility that PSB 603 acts as a negative allosteric modulator of A2BAR suggests new approaches to the development of therapeutic agents to treat conditions where adenosine levels are high.

1. Introduction

Adenosine acts via four (A1, A2A, A2B and A3) specific G protein-coupled receptors (GPCRs) [1]. The A1 and A3 receptors couple to Gi/o proteins and inhibit adenyl cyclase activity whilst the A2A and A2B receptors preferentially couple to Gs proteins and stimulate the formation of cyclic AMP (cAMP) [1–3]. The crystal structure of the A2A Receptor (A2AR) in both antagonist [4] and agonist [5] bound conformations has been determined in recent years. The adenosine A2B Receptor (A2BAR), which is closely related to the A2AR, is the least well defined of the four adenosine receptors and has low affinity for the endogenous agonist, adenosine [3,6]. A2BARs have been reported to have important roles in inflammation, fibrosis, angiogenesis and tumour progression [3,7–11] making them an important therapeutic target for drug discovery.
2. Materials and methods

2.1. Cultured cells

The CAMP GloSensor™ (20F) biosensor [26] expressed in HEK293 (HEK293G) cells was obtained from Promega (Madison, WI). HEK293G cells were maintained in Dulbecco modified eagles medium (DMEM) supplemented with 2 mM L-glutamine, 10% FCS (fetal calf serum) and 200 μg/ml hygromycin B at 37 °C 5% CO2. Once confluent, cells were dislodged from the flask surface by gentle shaking after incubation in 0.25% trypsin and cell pellet formed following 5 min 1000 g centrifugation. For the GloSensor™ assay, cells were resuspended in DMEM supplemented with 2 mM L-glutamine and 10% FCS and seeded at a density of 35000 cells/well on poly-I-lysine treated clear bottomed white walled 96 well plates. Cells were incubated at 37°C 5% CO2 overnight prior to assay.

2.2. GloSensor™ assay

The GloSensor™ assay was carried out as per manufacturer’s instructions (Promega, Madison, WI, USA). Briefly, this was as follows: Media was aspirated and cells were incubated in 100 μl HBSS (HEPES buffered saline solution pH 7.45; Sodium pyruvate 2 mM, NaCl 145 mM, β-Glucose 10 mM, KCl 5 mM, MgSO4 ·7H2O 1 mM, HEPES 10 mM, CaCl2 1.7 mM, NaHCO3 1.5 mM) containing 4–6% GloSensor™ CAMP reagent and incubated for 2 h at final experimental temperature of 35°C. Luminescence was measured on an EnVision™ Multilabel Plate Reader (Perkin Elmer, Massachusetts, USA) continuously over 60 min, averaging 1 read per well every 1.5 min, following the addition of 100 μl HBSS in the presence or absence of forskolin (10 nM–10 μM), NECA (5′-(N-Benzylxanthine)adenosine 10 nM–30 μM), Adenosine (100 nM–100 μM), BAY 60-6583 (2-[[6-Amino-3,5-dicyano-4-[[4-(cyclopropylmethoxy)phenyl]-2-pyridinyl]thio]aceticamide, 1 μM–30 μM) or CGS 21680 (4-[2-[[6-Amino-9-[[N-ethyl-[2-D-ribofuranosylamidosy]-9H-purin-2-yl][amino] ethyl]benzene propanoic acid hydrochloride, 30 nM–30 μM). Antagonist action was monitored following 30 min pre-incubation with HBSS in the presence or absence of XAC (xanthine amine congener), PSB 603 ([8-[4-[(4-Chlorophenyl)piperazidine-1-sulfonfyl]phenyl]-1-propylxanthine), ZM 241385 (4-[2-[[6-Amino-2-(2-furyl)]1,2,4-triazolo[2,3-a][1,3,5]triazin-5-ylamino]ethyl]phenylsulfoxide, 30 nM–30 μM). Determination of agonist potency, antagonist affinity and equilibrium dissociation constants were made by fitting data within GraphPad Prism version 5.03 for Windows (GraphPad Software, San Diego California USA, www.graphpad.com).

To obtain the antagonist equilibrium dissociation constants (Kb) a modified form of the Gaddum equation was used as described by Lazareno and Birdsall [31]:

\[ K_b = \frac{IC_{50}}{A_c/E_C - 1} \]

where IC_{50} is the molar concentration of antagonist (B) required to decrease by 50% the response mediated by the fixed molar concentration of agonist (A) in the absence of antagonist; and EC_{F} the molar concentration of agonist that, in the absence of antagonist, mediated the same response as that obtained in the presence of an IC_{50} concentration of antagonist. Agonist concentration response curves were simultaneously obtained (in the absence of antagonist).
Estimated affinity values ($K_B$) were also calculated from the shift of the agonist concentration response curves in the presence of a fixed concentration of antagonist using the following equation:

$$DR = 1 + \frac{[B]}{K_B}$$

where DR (dose ratio) is the ratio of the agonist concentration required to stimulate an identical response in the presence and absence of antagonist, [B].

Statistical significance was determined, where appropriate, using Student’s $t$-test, linear regression or one-way ANOVA with either Bonferroni’s (Table 1) or Dunnett’s (Table 2) multiple comparison test if $p < .05$ (statistically significant). A minimum of

### Table 1

| Agonist      | pIC$_{50}$ | IC$_{50}$ (nM) | -Log $K_B$ | KB (nM) |
|--------------|------------|----------------|------------|---------|
| XAC          | 6.93 ± 0.10 (6) | 14.4 ± 3.7 | 7.11 ± 0.10 (5) | nd |
| PSB 603      | 7.53 ± 0.22 (6) | 5.3 ± 2.0 | 9.0 ± 1.7 |
| ZM 241385    | 8.50 ± 0.22 (6) | 8.08 ± 0.10 (5) | nd | |
| SCH 58261    | 8.08 ± 0.10 (5) | nd | nd | |
| CGS 21680    | 7.02 ± 0.09 (5) | nd | 8.85 ± 0.18 (7) | 7.64 ± 0.11 (8) |
| Adenosine    | 7.89 ± 0.09 (5) | nd | 9.72 ± 0.18 (7) | 8.51 ± 0.11 (8) |
| BAY 60-6583  | 7.15 ± 0.12 (4) | 7.56 ± 0.43 (5) | 7.66 ± 0.14 (5) | nd |
| CGS 21680    | 97.0 ± 47.0 | 7.48 ± 0.12 (4) | 7.89 ± 0.43 (5) | 7.99 ± 0.14 (5) | nd |
| Adenosine    | 7.86 ± 0.13 (6) | 66.3 ± 55.7 | 13.2 ± 5.0 |
| BAY 60-6583  | 173.8 ± 33.9 | 7.50 ± 0.10 (6) | 8.55 ± 0.13 (6) | 7.74 ± 0.16 (6) | nd |
| NECA         | 6.39 ± 0.04  | 112.43 ± 3.08 | 4.97 ± 0.04 | 107.33 ± 3.67 |
| PSB 603      | 7.11 ± 0.10 (5) | 49.8 ± 19.1 | 84.4 ± 15.8 |
| ZM 241385    | 8.08 ± 0.10 (5) | 5.3 ± 2.0 | 9.0 ± 1.7 |
| SCH 58261    | 9.0 ± 1.7 |
| CGS 21680    | nd | 8.85 ± 0.18 (7) | 7.64 ± 0.11 (8) |
| Adenosine    | 9.72 ± 0.18 (7) | 8.51 ± 0.11 (8) |
| BAY 60-6583  | 7.66 ± 0.14 (5) | nd | nd | |
| CGS 21680    | 7.64 ± 0.11 (8) | 3.8 ± 0.8 |
| Adenosine    | nd | nd |
| BAY 60-6583  | 24.5 ± 7.9 |

IC$_{50}$ values and apparent dissociation equilibrium constants ($K_B$) were calculated from NECA, CGS 21680, adenosine and BAY 60-6583 competition curves alongside agonist concentration curves in the absence of antagonist. Data are expressed as mean ± S.E.M. of $n$ separate experiments (shown in parentheses). The apparent equilibrium dissociation constant for ZM 241385 following CGS 21680 stimulation is significantly different to that observed following NECA, BAY 60-6583 and adenosine stimulation ($p < .0001$; 1-way ANOVA). nd – Not determined because of lack of antagonism (see Fig. 6).

### Table 2

| PSB 603 (nM) | NECA pEC$_{50}$ | E$_{max}$ | Adenosine pEC$_{50}$ | E$_{max}$ | BAY 60-6583 pEC$_{50}$ | E$_{max}$ |
|--------------|----------------|----------|----------------------|----------|----------------------|----------|
| 0            | 5.77 ± 0.08 | 112.43 ± 3.08 | 4.97 ± 0.04 | 107.33 ± 3.67 | 6.39 ± 0.04 | 104.40 ± 5.14 |
| 30           | 5.66 ± 0.20 | 93.60 ± 8.38 | 4.56 ± 0.08 | 99.97 ± 10.83 | 5.80 ± 0.18 | 82.23 ± 1.64 |
| 100          | 5.86 ± 0.13 | 53.59 ± 8.68 | 4.34 ± 0.08 | 67.72 ± 5.94 | 5.34 ± 0.22 | 68.66 ± 6.78 |
| 300          | 5.68 ± 0.25 | 43.22 ± 7.60 | 4.03 ± 0.13 | 57.36 ± 6.13 | 4.44 ± 0.13 | 99.35 ± 26.61 |

pEC$_{50}$ and E$_{max}$ values obtained for NECA and adenosine obtained in the presence of increasing concentrations of PSB 603. EMAX values are expressed as a percentage of the response obtained with 10 µM NECA, 100 µM adenosine or 10 µM BAY 60-6583. Significant differences to that seen in the absence of antagonist with each agonist are indicated ("p < .01 , ""p < .0001, 1-way ANOVA). Data are expressed as mean ± S.E.M. of 4 (NECA), 7 (adenosine) or 3 (BAY 60-6583) separate experiments.

---

**Fig. 1.** Forskolin – and NECA – stimulated cAMP Glosensor luminescence. (a) Glosensor luminescence time courses following stimulation by increasing forskolin (10 µM) or NECA (10 µM). Data are mean ± S.E.M. of triplicate determinations obtained in a single representative experiment and expressed as relative luminescence units (RLU). Similar data were obtained in 8 (Forskolin) and 21 (NECA) separate experiments. (b) Representative concentration response curve for NECA obtained from triplicate determinations in a single experiment. Bars show the peak luminescence response to 10 µM forskolin (F) and that seen with vehicle alone (V). Similar data were obtained in 21 separate experiments.
three independent experiments was undertaken for all experimental work. This was based on the variance of the data obtained and power analysis that predicted a high probability of observing small differences in measured parameters. For example, the probability of detecting a change in pEC50 of 0.5 (3-fold) with n = 3 is 0.89. For n = 4 this increased to 0.96.

2.4. Drugs, chemical reagents and other materials

GloSensor™ cAMP Human Embryonic Kidney 293 cell line (Hek293G) and GloSensor™ cAMP Reagent were obtained from Promega (Wisconsin, USA). Forskolin, NECA, Adenosine, XAC and SCH 58261 were from Sigma-Aldrich (Missouri, USA). PSB 603, ZM 241385, BAY 60-6583 and CGS 21680 hydrochloride were from Tocris Bioscience (Bristol, UK). Adenosine Deaminase (ADA) was from Roche (Mannheim, Germany). Hygromycin B was from Invitrogen (Paisley, UK). L-glutamine, trypsin and FCS were from Lonza (Verviers, Belgium). All other chemicals were from Sigma-Aldrich (Missouri, USA).

3. Results

3.1. Kinetic profile of forskolin- and NECA- stimulated GloSensor™ luminescence in Hek293G cells

The effect of direct activation of adenylyl cyclase by forskolin on cAMP production and subsequent GloSensor™ luminescence in Hek293G cells is shown in Figs. 1a and 2a. Forskolin (10 μM) stimulated a concentration-dependent increase in luminescence which was followed (after achievement of the peak response) by a slow decline in the luminescence signal (Figs. 1a and 2a). We have previously reported that the HEK-293 cells express an endogenous adenosine A2aAR [21]. Stimulation of this receptor via the non-selective adenosine receptor agonist NECA also elicited a concentration-dependent increase in luminescence (Fig. 1b).

Whilst the magnitude of raw luminescence observed was dependent on biosensor expression level and GloSensor™ substrate concentration in a given experimental plate, the luminescent output afforded by 10 μM NECA was consistently greater (P < 0.05, unpaired t-test) than that of 10 μM forskolin and both were considerably greater than that observed with vehicle (HBSS) alone (Fig. 1a). It was evident that the rate of luminescent decay at the two highest NECA concentrations tested (10–30 μM) was markedly greater than that observed with a lower concentration of NECA (3 μM) giving an equivalent sized response (Fig. 2b). This was not seen with forskolin (Fig. 2a). The most likely explanation for this phenomenon is that receptor desensitization is occurring at the highest concentrations of NECA employed in this study. To investigate the rate of decline of the GloSensor™ response upon termination of A2aAR stimulation, as would occur when the agonist is removed or the receptor desensitized, we investigated the effect of addition of adenosine deaminase (ADA), an enzyme that metabolises adenosine to inosine, on an established adenosine response.
performed in triplicate. RLU; raw luminescence units. Obtained (arrow). Data represent mean ± S.E.M. of 6 separate experiments each measured in the same experiment. (Fig. 3). The addition of 2 U ml⁻¹ ADA at the peak response to adenosine rapidly reduced the luminescence output to basal levels within a few minutes (Fig. 3). In contrast, addition of HBSS in place of ADA resulted in a slow decline (Fig. 3) similar to that seen with forskolin or 3 μM NECA alone (Fig. 2a–b).

3.2. Characterisation of A2BAR and A2AAR responses in the HEK293G cell line

Concentration-response curves for agonist-stimulated cAMP Glosensor responses are shown in Fig. 4, with the selective A2B agonist BAY 60-6583 behaving a partial agonist relative to that of the endogenous agonist adenosine and its analogue NECA. Most notably the A2AAR-selective agonist CGS 21680 was able to stimulate a small but significant response within the HEK293G cell line (18.6 ± 4.5% that obtained with NECA; n = 12; P < 0.01; paired t test relative to basal), suggesting that the HEK293G cell line contained a mixed population of A2AAR and A2BAR. Interestingly, BAY 60-6583 gave a similar time course (providing evidence of desensitization at higher agonist concentrations) to that observed with NECA (Fig. 2c) whilst CGS 21680 did not (Fig. 2d). In addition the concentration-response curve for NECA had a Hill slope significantly less than unity (0.75; p < 0.001; Partial F test) which would be consistent with the presence of more than one component, similar to that seen previously in HMC-1 cells, which also expresses both A2AAR and A2BAR subtypes [32].

The partial agonist nature of the response to the A2B-selective agonist BAY 60-6583 at the A2AAR was confirmed in combination experiments with NECA (Fig. 5a). Thus, increasing concentrations of BAY 60-6583 were able to antagonise the response to a fixed concentration of NECA (10 μM) whilst a fixed concentration of BAY 60-6583 (10 μM) was able to shift the concentration-response curve to NECA to higher agonist concentrations (Fig. 5a). In marked contrast, the responses to the A2B-selective agonist BAY 60-6583 and the A2A selective agonist CGS 21680 were simply additive at low concentrations of each agonist, but reached a maximum that appeared to be entirely determined by the maximum response to BAY 60-6583 (Fig. 5b). These data suggest that the overall response to a combination of A2A and A2B receptor stimulation is largely determined by the maximum A2B signal in this cell line.

To investigate this further we examined the effect of subtype-selective antagonists on the responses to 10 μM NECA, 10 μM adenosine, 1 μM BAY 60-6583 or 1 μM CGS 21680 (Fig. 6). Pre-incubation with the non-selective adenosine receptor antagonist XAC inhibited the response to 10 μM NECA in a concentration-dependent manner, completely abolishing the response at 10 μM XAC (Fig. 6a). Similarly, the highly selective A2BAR antagonist PSB 603 produced a concentration-dependent inhibition of the NECA response, however the maximal inhibition achieved was only 81.7 ± 2.4% (n = 7, 1-way ANOVA P < .001 when compared to the response following stimulation with vehicle alone) of the maximal response to NECA (Fig. 6a). It is unlikely that this residual response following pre-incubation with the highest PSB 603 concentration is due to an A2AAR population since the A2AAR antagonist ZM 241385 also produced a concentration dependent inhibition of the response to NECA with complete inhibition at 10 μM (Fig. 6a). However the equilibrium dissociation constant obtained following ZM 241385 pre-incubation was entirely consistent with an A2BAR-mediated response (Table 1; [24,33]). Consistent with this suggestion, the more selective A2BAR antagonist SCH 58261 [34] failed to inhibit the response to NECA at all concentrations studied (Fig. 6a). Inclusion of 100 nM SCH 58261 in the competition curve obtained with PSB 603 did not produce a greater maximal inhibition of the response to NECA (Fig. 7).

Antagonism of the response to adenosine and BAY 60-6583 produced profiles that resembled that of NECA (Fig. 6b-c). Similar to the data obtained with NECA, 10 μM PSB 603 produced only 80.5 ± 3.0% inhibition of the response to 10 μM adenosine (Fig. 6b, 1-way ANOVA P < .001 when compared to the response following stimulation with vehicle alone). SCH 58261 appeared to enhance the production of cAMP at lower concentrations whilst inhibiting approximately 35% of the adenosine response at the highest concentration tested, although neither effect was statistically significant. SCH 58261 was a weak antagonist of the response to BAY 60-6583. The response to this agonist was potently antagonised by PSB 603 and was able to completely abolish the response to
BAY 60-6583 (Fig. 6c). Typical A2AR pharmacology was observed for responses to the selective A2AR agonist, CGS 21680 (Fig. 6d). XAC, ZM 241385 and SCH 58261 conferred complete concentration-dependent antagonism of the CGS 21680 response. The highly selective A2BAR antagonist, PSB 603, was unable to inhibit the CGS 21680 response at any of the concentrations tested. Apparent equilibrium dissociation constants for the different antagonists from this analysis are shown in Table 1.

3.3. Mechanism of A2BAR antagonism by PSB 603

In order to further characterise the mechanism of action of these antagonists at the adenosine A2 receptor population within HEK293G cells, concentration-response curves were obtained for NECA, adenosine, BAY 60-6583 and CGS 21680 following pre-incubation with increasing concentrations of different antagonists. Pre-incubation with increasing concentrations of both XAC and ZM 241385 elicited parallel rightwards shifts of the concentration-response curves to NECA (Fig. 8a, b) consistent with a competitive interaction between agonist and antagonist at the A2BAR. Analysis of these shifts yielding pA2 (−log Kd) values of 7.50 ± 0.09 (n = 4) and 8.02 ± 0.10 (n = 3) for XAC and ZM 241385 respectively. These are similar to the values obtained in Table 1. In contrast, the A2AAR-selective antagonist SCH 58261 did not shift the NECA concentration-response curve to higher agonist concentrations, and only shifted the adenosine response curve at the highest concentration (100 nM) tested (Fig. 8c-d). However, both SCH 58261 and ZM 241385 competitively antagonised the responses to the A2A-selective agonist CGS 21680 (Fig. 8e,f) yielding pA2 (−log Kd) values of 7.79 ± 0.15 (n = 3) and 8.64 ± 0.12 (n = 5) for SCH 58261 and ZM 241385 respectively. Increasing concentrations of XAC and ZM 241385 (Fig. 8g-h) both gave sequential rightwards shifts of the concentration response curve for BAY 60-6583 at lower antagonist concentrations but significantly depressed the Emax at the highest antagonist concentrations used (Table 3; 1 µM, p < .0001 Fig. 8g, p < 0.001 Fig. 8h).

Increasing concentrations of the A2AR selective antagonist PSB 603 significantly depressed the maximum response to NECA (p < .01; Table 2; one-way ANOVA) but did not significantly affect the EC50 (Fig. 9a, Table 2). PBS 603 also appeared to depress the maximum response to adenosine (p < .01; Table 2), however this was accompanied with a small significant shift of the EC50 value to higher against concentrations (Fig. 9b, Table 2). PSB 603 produced a larger shift in the EC50 for BAY 60 6583 (Fig. 9c) although the effect on the smaller maximum response of BAY 60 6583 was not well defined (Table 2). PSB 603 pre-incubation, however, did not affect the response to forskolin (Fig. 9d) or CGS 21680 (Fig. 9e).

The non-competitive antagonism of the NECA- and adenosine-mediated stimulation of cAMP production by PSB 603 suggests a negative allosteric mode of action at A2ARs. This is consistent with the incomplete attenuation of the response to NECA and adenosine shown in Fig. 6a and b, indicative of a saturable allosteric effect. To further investigate this phenomenon, we have also looked in detail at the kinetics of the response to NECA obtained in the presence of different concentrations of PSB 603 (Fig. 10). In comparison to the kinetics of the antagonism obtained with ZM 241385, there are two characteristics of the kinetics obtained with NECA in the presence of PSB 603 which are notable: (1) the antagonism by PSB 603 of the peak response to NECA reaches a limiting level leaving a residual response (circa 20%) (Fig. 10a) that is not observed with ZM 241385 (Fig. 10b) and (2) the time to the peak NECA response decreases in the presence of increasing concentrations of PSB 603 (Fig. 10a).

4. Discussion

In the present study we have used a real-time kinetic assay of changes in cAMP-stimulated PKA activation (GloSensor™ [25,26]) to investigate the molecular pharmacology of the A2AR-selective antagonist PSB 603 [6,16] in HEK 293 cells, endogenously expressing the human A2AR [21]. The GloSensor™ biosensor provided a robust kinetic profile of the responses to forskolin and NECA that were concentration dependent and characterised by a peak in luminescence occurring between 5 and 20 min. BAY 60-6583 acted as a partial agonist of the A2AR cAMP response in these cells. This was evident from both the lower
maximum response obtained relative to NECA and the ability of high concentrations of BAY 60-6583 to antagonise the response to a high concentration of NECA (Fig. 5a). Hinz et al., have also observed partial agonism with BAY 60-6583 in both endogenous and transfected lines [35], although Thim et al. [6] reported a full agonist response which would be expected at the higher receptor expression levels achieved with retroviral transfection approaches.

A notable feature of the response to high concentrations of NECA and BAY 60-6583 was that the decay in GloSensor™ luminescence was more rapid than that seen with lower agonist concentrations or indeed with all concentrations of forskolin. This is most likely a consequence of receptor desensitization at the high concentrations of NECA or BAY 60-6583 employed and suggests that the GloSensor™ system is accurately reporting the dynamic state of cAMP levels within the cells, and hence the extent of receptor activation. To examine receptor activation more directly we were able to use adenosine as the agonist and show that the luminescence signal rapidly declines to basal levels when the adenosine metabolising enzyme adenosine deaminase is added at the peak of the agonist response. Without the continued stimulus on the active receptor, residual cAMP is rapidly exported from the cell and/or hydrolysed by phosphodiesterases. It follows therefore that

Fig. 6. Antagonism of agonist-stimulated cAMP GloSensor responses by increasing concentrations of adenosine receptor antagonists. Competition curves for (a) NECA (10 μM), (b) adenosine (10 μM), (c) BAY 60-6583 (1 μM), (d) CGS 21680 (1 μM) stimulated cAMP responses following 30 min pre-incubation with XAC, PSB 603, ZM 241385 or SCH 58261. Data represent mean ± S.E.M of the peak luminescence response in individual experiments carried out in triplicate. Data are expressed as% of the peak luminescence response to each agonist obtained in the absence of antagonist for (a) seven (PSB), six (XAC), five (ZM 241385) or four (SCH 58261) separate experiments performed in triplicate. The residual response following 10 μM PSB 603 pre-incubation is significantly different to that seen with following stimulation with vehicle alone (1 way ANOVA, *P < .001); (b) of four (XAC), five (PSB 603, ZM 241385) or six (SCH 58261) separate experiments performed in triplicate. The residual luminescence response following 10 μM PSB 603 pre-incubation is significantly different to that seen with following stimulation with vehicle alone (1 way ANOVA, **P < .001); (c) five (XAC, ZM 241385, SCH 58261) or seven (PSB 603) separate experiments performed in triplicate; (d) five (XAC), six (PSB 603), seven (SCH 58261) or eight (ZM 241385) separate experiments performed in triplicate.

Fig. 7. The influence of SCH 58261 on the inhibition of NECA-stimulated cAMP production by PSB 603. Inhibition of the peak NECA (10 μM) stimulated responses following 30 min pre-incubation with the A2b selective antagonist PSB 603 (n = 4) in the presence or absence of the A2a selective antagonist SCH 58261 (100 nM). Data represent mean ± S.E.M of the peak luminescence response in individual experiments carried out in triplicate. Data are expressed as a percentage of the peak luminescence response to 10 μM NECA obtained in the absence of antagonist in each individual experiment.
Fig. 8. Influence of adenosine receptor antagonists on concentration-response curves to NECA, Adenosine, CGS 21680 and BAY 60-6583. NECA (a-c), Adenosine (d), CGS 21680 (e-f) and BAY 60-6583 (g-h) concentration response curves were obtained in the presence and absence of increasing concentrations of (a,g) XAC, (b,f,h) ZM 241385 or (c,e) SCH 58261. Values are mean ± S.E.M. of (a,f-h) five, (b,d) four or (c,e) three separate experiments carried out in triplicate. Data represent peak luminescence response and are expressed as a percentage of the peak luminescence response to 10 μM NECA, 100 μM Adenosine, 10 μM CGS 21680 or 10 μM BAY 60-6583 obtained in the absence of antagonist in each individual experiment.
the increased rate of luminescent decay observed with the higher NECA or BAY 60-6583 concentrations could result from a reduced pool of active receptor which would be apparent due to desensitization of the receptor. This A2BAR rapid agonist-driven desensitization has been noted previously and has been shown to be mediated by GRK2 that leads to β-arrestin-2 dependent receptor internalisation and subsequent re-sensitisation or degradation [36–39].

Consistent with previous reports [21], a pharmacological analysis of the GloSensor™ responses to NECA and adenosine indicated that they were largely mediated by A2BAR. The responses were antagonised by the A2BAR selective antagonist PSB 603. The selective A2AAR antagonist ZM 241385 only antagonised responses to NECA and adenosine at higher concentrations (pKi = 8.1 and 7.9 respectively; Table 1) than those required to selectively inhibit the A2BAR (pKi > 9.0; [2433]). Furthermore, the more selective A2BAR antagonist SCH 58261 [34] failed to inhibit the response to NECA at all concentrations studied in keeping with its known affinity for the A2BAR (pKi 6.0; [24]). A small inhibition of the responses to BAY 60-6583 and adenosine by SCH 58261 was only observed at the highest concentration of this A2BAR-antagonist used. This is likely to be due to the fact that SCH 58261 will start to inhibit the A2BAR receptor at concentrations in the micromolar range. The A2BAR–selective agonist CGS 21680, however, was able to stimulate a small response in these cells (18.6% of that achieved with NECA) and this had an antagonist profile (Fig. 6d) consistent with an A2BAR–mediated response. This response to CGS 21680 was antagonised competitively by ZM 241385 and SCH 58261 with pKi values of 9.4 and 8.2 respectively (Fig. 8e) but was not affected by PSB 603 at concentrations up to 10 µM. Taken together, these data are consistent with the presence of both A2BARs and A2BARs in HEK 293G cells regulating the formation of cAMP.

It was notable that both XAC and ZM241385 decreased the EMAX for BAY 60-6585 at the highest concentrations used. This is likely to be a result of a combination of: (a) the partial agonist nature of BAY 60-6585; (b) the transient nature of the GloSensor cAMP response produced by BAY 60-6583 and (c) the long residence time on the receptor of the two antagonists at high concentrations leading to hemi-equilibrium conditions. i.e. At the highest concentration of XAC and ZM241385 used, it is likely that the antagonist dissociates too slowly to allow the increasing agonist concentrations to reach equilibrium and overcome the antagonism before the agonist response wanes.

The presence of a 20% contribution from A2BAR to the cAMP responses to NECA and adenosine (predicted by the data obtained with CGS 21680) in this cell line suggests that only an 80% inhibition of these latter two agonists would be expected with the highly selective A2BAR antagonist PSB 603. This was what was observed (Fig. 6). However, inclusion of 100 nM SCH 58261 along with PSB 603 (Fig. 7) gave no indication of an A2BAR component in the response to NECA. This was also the case when concentration-response curves to NECA were analysed in the presence of increasing concentrations of SCH 58261 (Fig. 8c). These data suggest that cAMP responses to NECA and adenosine are only mediated via the A2BAR in this endogenously expressing cell line. The most likely explanation for the failure to observe a significant A2BAR component in the responses to NECA and adenosine is that a rapid A2BAR heterologous desensitization occurs [40] as a result of the activation of A2BAR.

The ability of A2BAR activation to over-ride any concomitant activation of A2AAR is also supported by the data obtained with BAY 60-6583 and CGS 21680 in combination (Fig. 5). In Fig. 5a a classical demonstration of the partial agonist effect of BAY 60-6583 was demonstrated. However, in Fig. 5b where the interaction between BAY 60-6583 and CGS 21680 is investigated, the responses to the two agonists were simply additive at low concentrations of each agonist, but reached a maximum that was entirely determined by the maximum response to BAY 60-6583. These data support the contention that the overall response to a combination of A2A and A2B receptor stimulation is largely determined by the larger A2B signal in this cell line.

An alternative explanation for the limited 80% inhibition of the cAMP responses to NECA and adenosine observed with PSB 603 (but not with XAC or ZM 241385) is that it is acting allosterically and the negative cooperative effect reaches a saturable effect [17–20]. In keeping with this hypothesis, the effect of increasing concentrations of PSB 603 on the concentration responses curves to NECA (Fig. 9a) and adenosine (Fig. 9b) were not consistent with competitive antagonism. In the case of NECA, the maximal response was significantly decreased by increasing concentrations of PSB 603 without significant effect on the pEC50 values (Table 2). The decrease in maximal response obtained with PSB 603 was not a consequence of off-target effects since concentration-response curves to both forskolin and CGS 21680 were completely unaffected at concentration of PSB 603 up to 300 nM. Furthermore, the small shift in pEC50 that accompanied the marked reduction in EMAX observed in response to adenosine is consistent with the probe dependence (i.e. which ligand is occupying the orthosteric site) of an allosteric mechanism of action [17–20].

As previously reported [35], BAY 60-6583 acted as a partial A2BAR agonist in the present studies. Interestingly, PSB 603 was able to completely attenuate the GloSensor responses to this lower efficacy agonist. However, as with the more efficacious agonists NECA and adenosine, the antagonism produced by PSB 603 of the BAY 60-6583 responses was not completely compatible with a simple competitive interaction. These observations would be compatible with the probe dependence referred to above [17–20].

Analysis of the kinetic profiles of the responses to NECA in the presence and absence of PSB 603 or ZM 241385 also suggested a different mechanism of action for these two antagonists. In comparison to the kinetics observed with ZM 241385, the antagonism by PSB 603 reached a limiting level (evidence of saturation) leaving a residual response (circa 20%) to NECA that was not observed with ZM 241385. Furthermore, the peak response to NECA was obtained at shorter incubation times in the presence of increasing concentrations of PSB 203. This was not observed with ZM 241385 where the peak responses to NECA in the presence of 100 or 300 nM ZM

### Table 3

| Antagonist (nM) | XAC E<sub>max</sub> | ZM 241385 E<sub>max</sub> |
|----------------|----------------------|--------------------------|
| 0              | 6.42 ± 0.04          | 6.46 ± 0.08               |
| 100            | 5.88 ± 0.05“         | 5.85 ± 0.06“              |
| 300            | 5.65 ± 0.04“         | 5.67 ± 0.06“              |
| 1000           | 5.03 ± 0.18“         | 5.14 ± 0.12“              |

pEC<sub>50</sub> and E<sub>max</sub> values obtained for BAY 60-6583 obtained in the presence of increasing concentrations of XAC or ZM 241385. E<sub>max</sub> values are expressed as a percentage of the response obtained with 10 µM BAY 60-6583. Significant differences to that seen in the absence of antagonist with each agonist are indicated (“p < .01, “p < .001,”p < .0001 1-way ANOVA). Data are expressed as mean ± S.E.M. of 5 separate experiments.

<ref>Table 3</ref>
Fig. 9. Influence of PSB 603 on concentration-response curves to adenosine receptor agonists and forskolin. Influence of increasing concentrations of PSB 603 on the agonist concentration-response curves for (a) NECA, (b) Adenosine (c) BAY 60-6583, (d) forskolin (FSK) and (e) CGS 21680. Values represent mean ± S.E.M. obtained in (a) four, (b,e) seven or (c,d) six separate experiments carried out in triplicate. Data represent the peak luminescence response and are expressed as a percentage of the peak luminescence response obtained with 10 μM NECA, 10 μM adenosine, 1 μM BAY 60-6583, 10 μM FSK or 1 μM CGS 21680 in the absence of antagonist in each individual experiment.
421385 were obtained at later time points, as would be expected for a competitive antagonist. Taken together, these data suggest that the mechanism of action of PSB 603 at the A2BAR is due to a negatively cooperative effect on the binding affinity and/or efficacy of agonists acting via the orthosteric site. Previous works with 3H-PSB-603 [6,16] have provided some evidence that PSB 603 may bind to a different set of amino acids to those used by the endogenous ligand adenosine, and this would be consistent with an allosteric mechanism of action.

In conclusion, the data presented here suggest that PSB 603 acts as a highly selective negative allosteric modulator of A2BAR - mediated increases in cAMP accumulation in HEK 293 cells endogenously expressing the human A2BAR. Interestingly, other positive and negative allosteric modulators of this receptor have recently been reported [41]. Allosteric modulation of the human A2BAR therefore represents a novel route to the development of therapeutic agents to treat conditions such as inflammation and injury, J. Clin. Invest. 116 (2006) 2173–2182.

Fig. 10. Kinetic profile of NECA-stimulated cAMP GloSensor luminescence obtained in the presence of increasing concentrations of (a) PSB 603 or (b) ZM241385. Data (mean ± S.E.M.) are expressed as a percentage of the peak luminescence response to 10 μM NECA obtained in the absence of antagonist in six (PSB 603) or five (ZM 241385) separate experiments. In each experiment triplicate determinations were made.

Acknowledgements
This work was supported by the Medical Research Council (grant number G0800006). We thank Promega Corporation for supplying the HEK293G cells. LTM held a National Health and Medical Research Council (NHMRC) postdoctoral research fellowship and is now an ARC DECRA Postdoctoral Research Fellow.

Author contributions
Participated in research design: Goulding, May, Hill. Conducted experiments: Goulding. Performed data analysis: Goulding, May, Hill.

Wrote or contributed to the writing of the manuscript: Goulding, May, Hill.

Statement of conflicts of interest
The authors declare no conflicts of interest.

References
[1] B.B. Fredholm, J.J. AP, K.A. Jacobson, J. Linden, C.E. Muller, International Union of Basic and Clinical Pharmacology. LXXXI. Nomenclature and classification of adenosine receptors—an update, Pharmacol. Rev. 63 (2011) 1–34.
[2] K.A. Jacobson, Introduction to adenosine receptors as therapeutic targets, Nat. Rev. Exp. Pharmacol. (2009) 1–24.
[3] C.E. Muller, K.A. Jacobson, Recent developments in adenosine receptor ligands and their potential as novel drugs, Biochim. Biophys. Acta 210 (2010) 1290–1308.
[4] V.P. Jaakola, M.T. Griffith, M.A. Hanson, V. Cherezov, E.Y. Chien, J.R. Lane, et al., The 2.6 Ångstrom crystal structure of a human A2A adenosine receptor bound to an antagonist, Science 322 (2008) 1211–1217.
[5] F. Xu, H. Wu, V. Katritch, G.W. Han, K.A. Jacobson, Z.G. Gao, et al., Structure of an agonist-bound human A2A adenosine receptor, Science 332 (2011) 322–327.
[6] D. Thimm, A.C. Schiedel, F.F. Sherbiny, S. Hinz, K. Hochheiser, D.C. Bertarelli, et al., Ligand-specific binding and activation of the human adenosine A(2B) receptor, Biochemistry 52 (2013) 726–740.
[7] S. Ryzhov, S.V. Novitskiy, R. Zaynagetidinov, A.E. Goldstein, D.P. Carbone, I. Biaggoni, et al., Host A(2B) adenosine receptors promote carcinoma growth, Neoplasia 10 (2008) 987–995.
[8] C.X. Sun, H. Zhong, A. Mohsenin, E. Morschi, J.L. Chunn, J.G. Molina, et al., Role of A2B adenosine receptor signaling in adenosine-dependent pulmonary inflammation and injury, J. Clin. Invest. 116 (2006) 2173–2182.
[9] J.H. Xiang, Z.C. Liu, D.S. Wang, Y. Chen, Y.L. Yang, K.F. Dou, Adenosine A(2B) receptor is highly expressed in human hepatocellular carcinoma, Hepatol. Res. 36 (2006) 56–60.
[10] H. Zhong, L. Belardinelli, T. Maa, D. Zeng, Synergy between A2B adenosine receptors and hyposia in activating human lung fibroblasts, Am. J. Respir. Cell Mol. Biol. 32 (2005) 2–8.
[11] Y. Zhou, D.J. Schneider, E. Morschi, L. Song, M. Pedrozzi, H. Karmouty-Quintana, et al., Distinct roles for the A2B adenosine receptor in acute and chronic stages of bleomycin-induced lung injury. J. Immunol. 186 (2011) 1097–1106.
[12] R.V. Kalla, J. Zabolick, Progress in the discovery of selectivity, high affinity A(2B) adenosine receptor antagonists as clinical candidates, Purinergic Signal 5 (2009) 21–29.
[13] G. Ortole, A. Martinelli, A2B receptor ligands: past, present and future trends, Curr. Top. Med. Chem. 10 (2010) 923–940.
[14] A. El Maatougui, L. Azuaje, M. Gonzalez-Gomez, G. Miguez, A. Crespo, C. Ortore, et al., Discovery of potent and highly selective A2B adenosine receptor antagonist chemotypes, J. Med. Chem. 59 (2016) 1967–1983.
[15] S. Basu, D.A. Barakwak, V. Ramdas, Y. Waman, M. Patel, A. Panmand, et al., Allosteric modulation of the human A2B adenosine receptor antagonists: design, synthesis and biological evaluation of novel xanthine derivatives, Eur. J. Med. Chem. 127 (2017) 986–996.
[16] T. Borrmann, S. Hinz, D.C. Bertarelli, W. Li, N.C. Florin, A.B. Scheiff, et al., 1-Alkyl-8-(piperazine-1-sulfonyl)phenylxanthines: development and characterization of adenosine A2B receptor antagonists and a new radioligand with subnanomolar affinity and subtype specificity, J. Med. Chem. 52 (2009) 3994–4006.
[17] T. Kenakin, Functional selectivity and biased receptor signaling, J. Pharmacol. Exp. Ther. 336 (2011) 296–302.
[18] T.P. Kenakin, 7TM receptor allosteric: putting numbers to shapeshifting proteins, Trends Pharmacol. Sci. 30 (2009) 460–469.
[19] P. Keov, P.M. Sexton, A. Christopoulos, Allosteric modulation of G protein-coupled receptors: a pharmacological perspective, Neuropharmacology 60 (2011) 24–35.
[20] L.T. May, K. Leach, P.M. Sexton, A. Christopoulos, Allosteric modulation of G protein-coupled receptors, Annu. Rev. Pharmacol. Toxicol. 47 (2007) 1–51.
[21] J. Cooper, S.J. Hill, S.P. Alexander, An endogenous A2B adenosine receptor coupled to cyclic AMP generation in human embryonic kidney (HEK 293) cells, Br. J. Pharmacol. 122 (1997) 546–550.
[22] K.N. Klotz, J. Hessling, J. Hegler, C. Owman, B. Kull, B.B. Fredholm, et al., Comparative pharmacology of human adenosine receptor subtypes – characterization of stably transfected receptors in CHO cells, Naunyn-Schmiedebergs Arch. Pharmacol. 357 (1998) 1–9.
[23] J. Linden, T. Thai, H. Figler, X. Jin, A.S. Roveba, Characterization of human A(2B) adenosine receptors: radioligand binding, western blotting, and coupling to G (q) in human embryonic kidney 293 cells and HMC-1 mast cells, Mol. Pharmacol. 56 (1999) 705–713.
[24] E. Ongini, S. Dionisotti, S. Gessi, I. Irenius, B.B. Fredholm, Comparison of CGS 15942, ZM 241385 and SCH 58261 as antagonists at human adenosine receptors, Naunyn Schmiedebergs Arch. Pharmacol. 359 (1999) 7–10.
[25] B.F. Binkowski, B.L. Butler, P.F. Stecha, C.T. Eggers, P. Otto, K. Zimmerman, et al., A luminescent biosensor with increased dynamic range for intracellular cAMP, ACS Chem. Biol. 6 (2011) 1193–1197.
[26] F. Fan, B.F. Binkowski, B.L. Butler, P.F. Stecha, M.K. Lewis, K.V. Wood, Novel genetically encoded biosensors using firefly luciferase, ACS Chem. Biol. 3 (2008) 346–351.

[27] E.M. Rosethorne, R.J. Turner, R.A. Fairhurst, S.J. Charlton, Efficacy is a contributing factor to the clinical onset of bronchodilation of inhaled beta (2)-adrenoceptor agonists, Naunyn Schmiedebergs Arch. Pharmacol. 382 (2010) 255–263.

[28] R. Irannejad, J.C. Tomshine, J.R. Tomshine, M. Chevalier, J.P. Mahoney, J. Steyaert, et al., Conformational biosensors reveal GPCR signalling from endosomes, Nature 495 (2013) 534–538.

[29] J.O. DiRaddo, E.J. Miller, H.A. Hathaway, E. Grajkowska, B. Wroblewska, B.B. Wolfe, et al., A real-time method for measuring cAMP production modulated by Gαi(o)-coupled metabolite glutamate receptors, J. Pharmacol. Exp. Ther. 349 (2014) 373–382.

[30] J. Gilissen, P. Geubelle, N. Dupuis, C. Laschet, B. Pirotte, J. Hanson, Forskolin-free cAMP assay for Gi-coupled receptors, Biochem. Pharmacol. 98 (2015) 381–391.

[31] S. Lazareno, N.J. Birdsall, Estimation of antagonist Ki from inhibition curves in functional experiments: alternatives to the Cheng-Prusoff equation, Trends Pharmacol. Sci. 14 (1993) 237–239.

[32] I. Feoktistov, I. Biaggioni, Pharmacological characterization of adenosine A2B receptors: studies in human mast cells co-expressing A2A and A2B adenosine receptor subtypes, Biochem. Pharmacol. 55 (1998) 627–633.

[33] S.M. Poucher, J.R. Keddie, P. Singh, S.M. Stoggall, C. Caulkett, G. Jones, et al., The in vitro pharmacology of ZM 241385, a potent, non-xanthine A2a selective adenosine receptor antagonist, Br. J. Pharmacol. 115 (1995) 1096–1102.

[34] C. Zocchi, E. Ongini, A. Conti, A. Monopoli, A. Negretti, P.G. Baraldi, et al., The non-xanthine heterocyclic compound SCH 58261 is a new potent and selective A2a adenosine receptor antagonist, J. Pharmacol. Exp. Ther. 276 (1996) 398–404.

[35] S. Hinz, S.K. Lacher, B.F. Seibt, C.E. Muller, BAY60-6583 acts as a partial agonist at adenosine A2B receptors, J. Pharmacol. Exp. Ther. 349 (2014) 427–436.

[36] S.J. Mundell, J.L. Benovic, E. Kelly, A dominant negative mutant of the G protein-coupled receptor kinase 2 selectively attenuates adenosine A2 receptor desensitization, Mol. Pharmacol. 51 (1997) 991–998.

[37] S.J. Mundell, R.P. Loudon, J.L. Benovic, Characterization of G protein-coupled receptor regulation in antisense mRNA-expressing cells with reduced arrestin levels, Biochemistry 38 (1999) 8723–8732.

[38] S.J. Mundell, A.L. Matharu, E. Kelly, J.L. Benovic, Arrestin isoforms dictate differential kinetics of A2B adenosine receptor trafficking, Biochemistry 39 (2000) 12828–12834.

[39] D.M. Peters, E.K. Gies, C.R. Gelb, R.A. Peterfreund, Agonist-induced desensitization of A2B adenosine receptors, Biochem. Pharmacol. 55 (1998) 873–882.

[40] T.M. Palmer, G.L. Stiles, Identification of an A2a adenosine receptor domain specifically responsible for mediating short-term desensitization, Biochemistry 36 (1997) 832–838.

[41] M.L. Trincavelli, C. Giacomelli, S. Daniele, S. Taliani, B. Cosimelli, S. Laneri, et al., Allosteric modulators of human A2B adenosine receptor, Biochim. Biophys. Acta 2014 (1840) 1194–1203.